Abbott pays $170 million for PanGenetics' anti-NGF antibody
This article was originally published in Scrip
Executive Summary
Abbott will pay $170 million up front to acquire a Phase I nerve growth factor (NGF) antibody from the Dutch antibody company PanGenetics. The deal, which is expected to close by the end of this year, also allows for a further $20 million in future milestone payments to PanGenetics.
You may also be interested in...
INTERVIEW: Finding Stars And Staying Independent, Biotech Veteran David Chiswell's Five Year Plan
David Chiswell has worked tirelessly to build up the British biotech industry for over 30 years. Now, as CEO of Kymab, he is looking to the future of the industry and how to find the stars of the future.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.